NetworkNewsBreaks – Newly Appointed Board of Dir
Post# of 69
On February 12, 2019 Jamieson Bondarenko, a recently appointed member of BriaCell Therapeutics’ (OTCQB: BCTXF) (TSX.V: BCT) Board of Directors, acquired 2,000,000 common shares of the company through the facilities of the TSX Venture Exchange at a price of $0.0975 per share for a total purchase price of $195,000. Bondarenko previously held 16,070,500 common shares of the company, representing about 9.8 percent of BriaCell’s issued and outstanding common shares. Following the acquisition, Bondarenko now has beneficial ownership of 18,070,500 common shares, representing approximately 11 percent of the company’s issued and outstanding common shares.
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer